Miles Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

Miles Capital’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-2,020	Closed	-$218K	–	190
2019 Q4	$218K	Sell	2,020 -37	-2%	-$3.96K	0.17%	164
2019 Q3	$201K	Sell	2,057 -2	-0.1%	-$225	0.17%	168
2019 Q2	$270K	Buy	2,059 +273	+15%	+$35.2K	0.22%	116
2019 Q1	$241K	Buy	+1,786	New	+$222K	0.21%	131
2018 Q4	–	Sell	-1,971	Closed	-$274K	–	188
2018 Q3	$274K	Buy	+1,971	New	+$247K	0.22%	121

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Miles Capital's ALXN Position: Q1 2020 in Review

Miles Capital sold out of Alexion Pharmaceuticals (ALXN) in Q1 2020, closing a stake of 2,020 shares — an estimated $218K sold.

Miles Capital first reported a position in ALXN in Q3 2018 and held it in 5 quarters. The position peaked at $274K in Q3 2018. 654 funds tracked by Wall St. Rank hold ALXN as of Q1 2020.

Miles Capital reported no remaining Alexion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Miles Capital sold 2,020 Alexion Pharmaceuticals shares in Q1 2020, an estimated $218K.
Miles Capital first reported a position in Alexion Pharmaceuticals in Q3 2018 and held it in 5 quarters.
Miles Capital's Alexion Pharmaceuticals position peaked at $274K in Q3 2018.
654 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2020.

Based on Miles Capital's 13F filing for Q1 2020, filed 13 May 2020.